Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, USA.
Am J Pathol. 2009 Nov;175(5):1984-92. doi: 10.2353/ajpath.2009.080515. Epub 2009 Oct 1.
Vascular endothelial growth factor receptor (VEGFR)-2 is a major stimulator of hemangiogenesis (HA), whereas VEGFR-3 stimulates lymphangiogenesis (LA). Contrary to this understanding, we demonstrate that implantation of pellets containing VEGFR-3-specific ligands (VEGF-C156S and recombinant murine VEGF-D) into the corneal stroma induce not only LA but also robust HA characterized by blood vessels that are positive for VEGFR-3 expression. The implantation of pellets containing VEGFR-3-specific ligands also leads to the recruitment of VEGF-A-secreting macrophages. Depletion of these infiltrating macrophages using clodronate-liposome administration shows a significant reduction in HA as well as LA. Blockade of either VEGFR-2 or VEGFR-3 signaling reduces both HA and LA; however, the percent reduction of HA is greater in the VEGFR-2 blockade group. In addition, in the VEGFR-3 blockade group, the percent reduction of HA is significantly greater with VEGFR-3-specific ligands than that by VEGF-A or VEGF-C. Collectively, our data suggest that VEGFR-3-specific signaling can induce new blood vessels, to which macrophages contribute a major role, and signify its potential as an additional therapeutic target to the existing VEGF-A/VEGFR-2 signaling-based antiangiogenesis strategies.
血管内皮生长因子受体 (VEGFR)-2 是促血管生成 (HA) 的主要刺激物,而 VEGFR-3 则刺激淋巴管生成 (LA)。与这种理解相反,我们证明将含有 VEGFR-3 特异性配体(VEGF-C156S 和重组鼠 VEGF-D)的小丸植入角膜基质中不仅会诱导 LA,还会诱导具有特征性的血管生成,这些血管对 VEGFR-3 表达呈阳性。植入含有 VEGFR-3 特异性配体的小丸还会导致分泌 VEGF-A 的巨噬细胞的募集。使用氯膦酸盐脂质体给药耗尽这些浸润的巨噬细胞会导致 HA 和 LA 明显减少。阻断 VEGFR-2 或 VEGFR-3 信号均可减少 HA 和 LA,但 VEGFR-2 阻断组中 HA 的减少百分比更大。此外,在 VEGFR-3 阻断组中,VEGFR-3 特异性配体引起的 HA 减少百分比明显大于 VEGF-A 或 VEGF-C。总之,我们的数据表明,VEGFR-3 特异性信号可以诱导新的血管,巨噬细胞在其中发挥主要作用,并表明其作为现有基于 VEGF-A/VEGFR-2 信号的抗血管生成策略的附加治疗靶点的潜力。